Weight loss drugs may help lower overdoses, alcoholism
Opinion
New weight loss drugs raise questions of access, costs
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs.
Could Weight-Loss Drugs Help Get People Back to Work? The U.K. Wants to Find Out.
The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.
Are Compounded Weight Loss Drugs on Their Way Out?
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and Zepbound.
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its shortage list. Here's what taking the drug of the list could mean for people taking tirzepatide or its compounded versions.
Offering Wegovy and other weight loss drugs on Medicare could cost $35 billion
Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions of dollars, according to a new report by the Congressional Budget Office (CBO).
Your employer may start covering weight-loss drugs soon
Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, according to a national survey conducted this year by Mercer, a human resources consulting firm.
Companies are more willing to consider covering weight-loss drugs
That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a growing number say they’re open to covering GLP-1 drugs, they’re still in the minority. Some 62% of the firms surveyed said they are “not likely” to begin coverage in the coming year.
Can Weight Loss Drugs Also Treat Addiction?
GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and alcohol intoxication, a large real-world study suggested.
Weight-loss drugs may reduce opioid and alcohol abuse by up to 50%, study finds
Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.
Weight loss drugs could help with alcohol, opioid addiction, study says
Drugs​ like Mounjaro and Ozempic, which many use for weight loss,​​ may also help patients suffering from addiction, according to a new study.
Weight-Loss Drugs Cut Drug and Alcohol Abuse, According to New Study
Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence that the drugs yield health benefits beyond diabetes and weight loss.
Popular weight-loss drugs like Ozempic could treat opioid overdose and alcohol intoxication
A new study found a link between new popular GIP/GLP-1 receptor agonists and a reduced rate of overdose or intoxication in ...
Washingtonians share how they afford pricey weight loss medications
Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...
UPI11d
Health plans at 1 in 5 large companies cover weight-loss drugs for employees
When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S.
Politico Europe3d
Can Ozempic help drug addicts, too? A mega new study suggests it might.
Weight-loss and diabetes drugs like Ozempic and Mounjaro could be used to treat drug and alcohol addiction in the future — ...